Welcome to our dedicated page for Neuronetics SEC filings (Ticker: STIM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Neuronetics, Inc. filings document the public reporting record for a Nasdaq-listed medical technology and healthcare company with common stock traded under STIM. Recent Form 8-K reports furnish operating results, investor presentation materials, executive appointments and retirements, compensation arrangements, restructuring charges, and material agreements tied to credit facilities and registration rights.
The company’s proxy materials describe annual meeting voting matters, director elections, auditor ratification, advisory executive compensation votes, and equity incentive plan approvals. Together with event reports, the filings disclose governance procedures, capital-structure matters, Nasdaq-listed security information, and contractual obligations associated with Neuronetics’ medical device and clinic-services operations.
Neuronetics (STIM) Q2-25 10-Q snapshot
Revenue jumped 132% YoY to $38.1 M as the December 2024 Greenbrook acquisition added clinic revenue (61% of sales). Treatment-session revenue grew 32% while NeuroStar device sales fell 13%. Gross margin compressed to 46.6% from 74.0% given the lower-margin clinic mix.
Operating loss improved slightly to $8.1 M, but higher interest cost (SOFR+7%) left net loss to shareholders at $10.1 M (-$0.15/sh); share count more than doubled after a February 2025 secondary offering that raised $18.9 M net. Six-month revenue rose 107% to $70.1 M, with a net loss of $22.8 M.
Cash & equivalents fell to $11.0 M (plus $6.5 M restricted) after a $20.5 M operating cash burn YTD. Long-term debt remains $55.5 M under the Perceptive facility, maturing 2029; leverage covenants commence Q1-26. Equity totals $31.5 M.
Management expects available cash and projected sales to fund operations for at least 12 months and anticipates cost synergies from Greenbrook.
Neuronetics, Inc. (STIM) filed an 8-K on 5-Aug-2025 announcing Amendment No. 3 to its July 2024 Credit Agreement with Perceptive Credit Holdings IV.
- Immediate liquidity: the amendment allows the company to draw a $10 million Tranche 2A term loan on the execution date (1-Aug-2025).
- Covenant relief: the minimum cash/liquidity requirement is reduced to $2 million through 30-Sep-2026, giving the company additional flexibility.
- Equity sweetener: Perceptive receives a warrant for 225,000 common shares; exercise terms were not disclosed in the filing.
Items 2.02 and 7.01 merely furnish (not file) the company’s Q2-25 earnings press release (Ex. 99.1) and an investor presentation (Ex. 99.2); no financial figures are included in this document.
Exhibits disclosed are: 10.1 (Amendment), 99.1 (press release), 99.2 (presentation) and 104 (iXBRL cover).